美國Access

美國癌癥患者護(hù)理公司Access Pharmaceuticals 治療癌癥患者口腔粘膜炎的MuGard

Access Pharmaceuticals is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one FDA-approved product, two products in Phase II clinical development, three products in preclinical development. Several of the company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.
While its primary focus is in oncology, Access' drug delivery technologies also yield candidates that enable and enhance the absorption of drugs by exploiting the body's own vitamin B-12 absorption system.
Mucositis is a frequent side-effect of cancer therapy for which there is no established treatment. MuGard ™ is Access' approved proprietary nanopolymer formulation for the management of mucositis. This ready–to–use rinse provides a soothing oral coating. A clinical study has shown that when MuGard is used by patients at the start of cancer therapy, the incidence and severity of mucositis are reduced. MuGard is available in Europe by prescription through Access' marketing partner, SpePharm. Access will be marketing MuGard in the United States in 2010, and marketing partners in Asia are advancing Regulatory approval of MuGard in South Korea and China.

Access is focusing its development effort on three products/technologies: ProLindac ™, Thiarabine, and Cobalamin ™. The company's lead development candidate for the treatment of cancer is ProLindac ™, a nanopolymer DACH platinum prodrug. ProLindac has successfully completed a European Phase II trial in patients with ovarian cancer, and Access and its Asian partners are planning to start Phase II combination studies shortly. Oxaliplatin （Eloxatin, Sanofi-Aventis） is the only DACH platinum currently approved; it has sales in excess of $2 billion.
Thiarabine; is a Phase II nucleoside analog with considerable potential for treatment of lymphoma and leukemia. Extensive preclinical data shows that Thiarabine has good efficacy in a variety of tumor models.
Cobalamin ™; is Access' proprietary nanopolymer oral drug delivery technology. Using a 'Trojan Horse' approach, the technology uses the body's natural vitamin B12 uptake mechanism in the gut to transport drugs that otherwise would have little or no oral bioavailability. The company is currently developing products for the oral delivery of insulin and human growth hormone （HGH）, and is collaborating with a number of companies to develop additional formulations of various other pharmaceutically-active compounds.